CT1812
COG0202
Phase 2 small_molecule completed
Quick answer
CT1812 for Alzheimer Disease is a Phase 2 program (small_molecule) at COGNITION THERAPEUTICS INC with 3 ClinicalTrials.gov record(s).
Program details
- Company
- COGNITION THERAPEUTICS INC
- Indication
- Alzheimer Disease
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed